Results 131 to 140 of about 52,376 (272)

Animal models of myasthenia gravis: utility and limitations

, 2016
Renato Mantegazza, Chiara Cordiglieri, Alessandra Consonni, Fulvio Baggi Neurology IV Unit, Neuroimmunology and Neuromuscular Disorders, Foundation IRCCS Neurological Institute “Carlo Besta”, Milan, Italy Abstract: Myasthenia gravis (MG) is ...
Cordiglieri C, Consonni A, Mantegazza R, Baggi F   +3 more
core  

A Pilot Study on Tocilizumab in Very-Late-Onset Myasthenia Gravis

, 2023
Ting-Ting Yang,1,* Ze-Yi Wang,1,* Ze-Xin Fan,1 Bo-Yi Yuan,1 Lin Ma,1 Jian-Feng Lu,1 Pen-Ju Liu,1 Yang He,2 Guang-Zhi Liu1 1Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, People’s Republic of China ...
Yang TT, Ma L, He Y, Yuan BY, Liu GZ, Fan ZX, Lu JF, Wang ZY, Liu PJ   +8 more
core  

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan, Pooja Patel, Jeva Cernova, Sarah Hogan, Jason Thomson, Efthymios Hadjimichael, Sharanpal Jeetle, Dorota Markiewicz, Michael Sheaff, Nilukshi Wijesuriya, Mark Hawthorne, Graeme Moir, Matthew Stodell, Kapil Bhargava, Suchitra Chinthapalli, Catherine A. Harwood   +15 more
wiley   +1 more source

Technique of the transcervical-subxiphoid-videothoracoscopic maximal thymectomy

Journal of Minimal Access Surgery, 2007
Background: The aim of this study is to present the new technique of transcervical-subxiphoid-videothoracoscopic "maximal"thymectomy introduced by the authors of this study for myasthenia gravis.
Zielinski Marcin, Hauer Lukasz, Kuzdzal Jaroslaw, Sosnicki Witold, Harazda Maria, Pankowski Juliusz, Nabialek Tomasz, Szlubowski Artur   +7 more
doaj  

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

Internal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W. Reddel, Sean Riminton, Douglas F. Johnson   +13 more
wiley   +1 more source

Mycophenolate mofetil for myasthenia gravis: a clear and present controversy

, 2008
Chad Heatwole, Emma CiafaloniDepartment of Neurology, The University of Rochester, Rochester, New York, USAAbstract: Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 10 years.
Emma Ciafaloni, Chad Heatwole
core  

Mapping of C5‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition

Immunology, EarlyView.
We identify four distinct C5 inhibitory epitopes, including two novel antibodies that selectively block membrane attack complex (MAC) assembly while preserving C5 cleavage and C5a generation. These findings establish selective MAC inhibition as a new therapeutic strategy for complement‐mediated diseases.
Rebekah Sian Cooke, Kok Yung Lee, Georgina Elizabeth Menzies, Masashi Mizuno, Bryan Paul Morgan, Wioleta Milena Zelek   +5 more
wiley   +1 more source

Factors Worsening the Course of Myasthenia: Latest Research and Insights

Neurologijos seminarai
Myasthenia (Latin: myasthenia gravis, MG) is an autoimmune disease that affects the neuromuscular junction, leading to pathological muscle fatigue. The main symptom of the disease is muscle fatigue, which becomes more pronounced after exertion and may ...
Viktorija Kutniauskaitė, Gabrielė Žilionytė, Evelina Grušauskienė   +2 more
doaj   +1 more source

Immune checkpoint inhibitor‐induced myasthenia gravis, myocarditis, and myositis: A case report

Clinical Case Reports
Key Clinical Message Immune checkpoint inhibitors can rarely lead to occurrence of myositis, myocarditis, and myasthenia gravis (MG). Early recognition and multidisciplinary management are crucial for optimal outcomes.
Arjun Basnet, Nava Raj Sharma, Sudarshan Gautam, Saral Lamichhane, Sajog Kansakar, Kripa Tiwari, Madalasa Pokhrel, Sehajpreet Singh   +7 more
doaj   +1 more source

The potential causes of myasthenia and fasciculations in severely ill ME/CFS patients: the role of disturbed electrophysiology

Frontiers in Physiology
Patients with severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are bedridden and suffer from hypersensitivities to light and noise, severe orthostatic intolerance reducing cerebral blood flow, and skeletal muscle symptoms, including ...
Klaus J. Wirth, Jürgen M. Steinacker
doaj   +1 more source